Breast Cancer to Increase rapidly over the Next Two Decades in the USA; New Ovarian and Breast Cancer Testing Kit Available

Genetic testing is now only available but also affordable for testing if one is at a higher risk of ovarian or breast cancer. Color Genomics has produced a $249 kit, which can analyze in all 19 genes and determine whether one is at a higher risk for cancer or not.

Despite an increasing number of campaigns and programs conducted by healthcare professionals worldwide on cancer awareness & prevention, a new study conducted by the US Government researchers has indicated that Breast Cancer is likely to increase by almost 50 percent in the US by 2030.

Philip S Rosenberg from the National Cancer Institute says that the only positive feedback from the study was the indication of lower incidence of estrogen receptor negative breast cancers, which include HER2 positive and triple negative cancers, which are considered as difficult to treat. Rosenberg added that the number of subtypes in breast cancers is going to increase.

Currently the estimated number of cancer patients are at 283,000 as recorded in 2011 which is likely to increase to a whopping 441,000 by 2030 with estrogen receptor positive cancer was likely to remain in the same proportion at just above 60% and estrogen receptor positive cancers, which don't spread to other locations would increase to 29% to the current 19%.

The study & its findings was presented by the Institute at the recently conducted Annual Meeting of the American Association for Cancer Research which was held in Philadelphia.

Estrogen receptor negative cancers would drop to 9% from current proportions of 17%. Although they were not unable to identify a cause for this decline Rosenberg stated that they have been encouraging clues that have been indicated.

The Demographics & Age distribution is also likely to vary in the future with cancer being 35% among Aged Women between 70 and 84 and women between 50 and 69 are likely to see a drop in the rate of incidence from 55% to 44%. This study has been well received, as it is a definitive step in creating a "proactive road map" for early detection, prevention and treatment for years to come.